Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73%). Side effects were not significant. Encainide appears to be an effective drug for these patients.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Electrophysiology|
|State||Published - Jan 1 1987|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine